Skip to main content
European Commission logo print header

Disruptive Innovation to Treat Alzheimer’s and Parkinson’s diseases: new target, new patented drug, new therapeutic strategy.

Project description

A chimeric peptide key to the treatment of Alzheimer's and Parkinson's diseases

Alzheimer’s and Parkinson’s diseases are both neurological illnesses caused by damaged brain cells. In the race to find a cure, clinical trials based on anti-amyloid plaques immunotherapies have been unsuccessful. The EU-funded AmInnovation offered a novel solution – AmyP53, a disruptive innovation that can block the very first step of these diseases. The project aimed to de-risk AmyP53 by evaluating its safety in animals. Through the project, the candidate therapeutic agent was synthesised and characterised for its chemical and biological properties and administered in male and female rats via the intravenous and intranasal routes. As expected, all outcomes were outstanding, demonstrating no single toxicity issue, which definitively does open the door for the first-in-human trials very soon.


Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the main culprits of these pathologies, do not provide a cure or even stop the progression of the diseases. All clinical trials based on anti-plaques immunotherapies have been unsuccessful. The reason for this global failure is quite simple: these strategies are based on the wrong targets. Indeed, there is no correlation at all between the neurological symptoms and the presence of amyloid plaques in the brain. Thus, the paradigm linking amyloid plaques to neurodegenerative diseases has been totally wrong.

AmyPore action plan has been totally different from these unsuccessful approaches. Firstly, we rely on top-level academic researchers who identified the real molecular mechanisms that are the direct cause of the diseases: the amyloid protein oligomers which are responsible for an overdose of calcium in brain cells (amyloid pores). Secondly, AmyPore has taken advantages of the recent artificial intelligence revolutions in neurosciences for identifying a new biological code and optimizing the design of AmyPore lead product candidate.

AmyPore solution, called “AmyP53” is the disruptive innovation that has demonstrated to be in the position to overcome these terrible diseases.
As a matter of fact, relying upon :
- an exclusive license, linked to an international patent owned by the inventors,
- recent scientific publications,
- and additional recent conclusive tests,

AmyP53 is :
- easy to test,
- easy to produce worldwide,
- easy to administer.

AmyP53 is not only one of the first drug that targets the oligomer cascade, it is the only one that can block the formation neurotoxic oligomers in the membrane of brain cells.

Call for proposal


See other projects for this call

Sub call




Net EU contribution
€ 50 000,00
Boulevard elie corradi 51
13240 Septemes-les-vallons

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00